General Information of This Drug (ID: DMJ6F5C)

Drug Name
XL019   DMJ6F5C
Synonyms
XL019; 945755-56-6; UNII-4L1AM42NVA; (S)-N-(4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide; 4L1AM42NVA; (2S)-N-[4-[2-[[4-(4-Morpholinyl)phenyl]amino]-4-pyrimidinyl]phenyl]-2-pyrrolidinecarboxamide; 945750-13-0; (2S)-N-[4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]phenyl]pyrrolidine-2-carboxamide; (2S)-N-[4-(2-{[4-(MORPHOLIN-4-YL)PHENYL]AMINO}PYRIMIDIN-4-YL)PHENYL]PYRROLIDINE-2-CARBOXAMIDE; C25H28N6O2; 2-Pyrrolidinecarboxamide, N-(4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)phe
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 3 [1]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Polycythemia vera DISB5FPO 2A20.4 Phase 1 [1]
------------------------------------------------------------------------------------

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7971).